Annual PSA tests fail to cut deaths

Routine screening does not reduce deaths from prostate cancer, according to new data from one of the largest, but most controversial, trials of PSA testing.

With follow-up now extended to 13 years, the US-based Prostate, Lung Colorectal, and Ovarian (PLCO) Cancer Screening Trial continues to show no difference in prostate cancer mortality between men screened annually and those screened sporadically.

Men screened routinely had a significantly higher overall incidence of prostate cancer, and a non-significantly lower incidence of high-grade cancers — suggesting